Shabana Habib, Gabriel Osborn, Zena Willsmore, Min Waye Chew, Sophie Jakubow, Amanda Fitzpatrick, Yin Wu, Khushboo Sinha, Hawys Lloyd-Hughes, Jenny L C Geh, Alastair D MacKenzie-Ross, Sean Whittaker, Victoria Sanz-Moreno, Katie E Lacy, Sophia N Karagiannis, Rebecca Adams
INTRODUCTION: Despite the success of immunotherapies for melanoma in recent years, there remains a significant proportion of patients who do not yet derive benefit from available treatments. Immunotherapies currently licensed for clinical use target the adaptive immune system, focussing on Tcell interactions and functions. However, the most prevalent immune cells within the tumor microenvironment (TME) of melanoma are macrophages, a diverse immune cell subset displaying high plasticity, to which no current therapies are yet directly targeted...
March 27, 2024: Expert Review of Clinical Immunology